189 related articles for article (PubMed ID: 31945303)
61. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.
Tan SF; Pearson JM; Feith DJ; Loughran TP
Expert Opin Ther Targets; 2017 Jun; 21(6):583-590. PubMed ID: 28434262
[TBL] [Abstract][Full Text] [Related]
62. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
Bruserud Ø; Aasebø E; Hernandez-Valladares M; Tsykunova G; Reikvam H
Expert Opin Drug Discov; 2017 Oct; 12(10):1053-1065. PubMed ID: 28748730
[TBL] [Abstract][Full Text] [Related]
63. [Recent advances in molecular targeted therapy for acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2021; 62(6):562-571. PubMed ID: 34219082
[TBL] [Abstract][Full Text] [Related]
64. Cell-surface proteomics for the identification of novel therapeutic targets in cancer.
Kuhlmann L; Cummins E; Samudio I; Kislinger T
Expert Rev Proteomics; 2018 Mar; 15(3):259-275. PubMed ID: 29343144
[TBL] [Abstract][Full Text] [Related]
65. Two decades of targeted therapies in acute myeloid leukemia.
Cucchi DGJ; Polak TB; Ossenkoppele GJ; Uyl-De Groot CA; Cloos J; Zweegman S; Janssen JJWM
Leukemia; 2021 Mar; 35(3):651-660. PubMed ID: 33589753
[TBL] [Abstract][Full Text] [Related]
66. What are the most promising new agents in acute myeloid leukemia?
Sallman DA; Lancet JE
Curr Opin Hematol; 2017 Mar; 24(2):99-107. PubMed ID: 28030373
[TBL] [Abstract][Full Text] [Related]
67. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
Laing AA; Harrison CJ; Gibson BES; Keeshan K
Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
[TBL] [Abstract][Full Text] [Related]
68. Emerging therapeutic drugs for AML.
Stein EM; Tallman MS
Blood; 2016 Jan; 127(1):71-8. PubMed ID: 26660428
[TBL] [Abstract][Full Text] [Related]
69. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
70. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl SR; Bullinger L; Rücker FG
Expert Rev Hematol; 2018 May; 11(5):361-371. PubMed ID: 29543073
[TBL] [Abstract][Full Text] [Related]
71. [Gene mutations in acute myeloid leukemia].
Yamaguchi H
Rinsho Ketsueki; 2016; 57(12):2535-2542. PubMed ID: 28090023
[TBL] [Abstract][Full Text] [Related]
72. Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials.
Caywood EH; Kolb EA
J Clin Oncol; 2015 Dec; 33(36):4238-9. PubMed ID: 26573081
[No Abstract] [Full Text] [Related]
73. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
74. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
75. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
76. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
77. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N; Cortes J; Kantarjian H; Ravandi F
Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
[TBL] [Abstract][Full Text] [Related]
78. [Comparison of proteomics between acute myeloid leukemia and acute lymphoid leukemia].
Xiao P; Zeng YY; Nie YF; Lin W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1353-6. PubMed ID: 22169282
[TBL] [Abstract][Full Text] [Related]
79. Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop.
Wang ES; Baron J
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):57-66. PubMed ID: 33275692
[TBL] [Abstract][Full Text] [Related]
80. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children.
Stratmann S; Vesterlund M; Umer HM; Eshtad S; Skaftason A; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Lindskog C; Cavelier L; Lehtiö J; Holmfeldt L
Leukemia; 2023 Mar; 37(3):550-559. PubMed ID: 36572751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
